Low and middle-income countries
International Liver Conference: Activists Demand Affordable Hepatitis C Treatment
Pills cost pennies, greed costs lives.
As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise the issue of access to hepatitis C treatment in LMICs. More
Nobody Left Behind
The importance of integrating people who inject drugs into HCV treatment programs. Arguments from a public health and human rights perspective.
"We estimate that around 2 million people who inject drugs globally need treatment immediately." More
1st Hepatitis C Virus World Community Advisory Board Report
14 July 2014 - By Odilon Couzin and Karyn Kaplan
Treatment activists held the first global LMIC-focused dialogue with pharmaceutical companies that produce HCV treatment, co-organized by TAG and the Asia Pacific Network of PLHA. More
Gilead’s License on Hepatitis C Drugs, Sofosbuvir and Ledipasvir: a Fool’s Bargain
Myths and facts
Gilead’s license is a fool’s bargain that inhibits access for nearly half the world’s HCV population. More
Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries
By Karyn Kaplan
A report, developed by TAG, presents a number of key strategies through real-world case studies and shows how HIV-targeted strategies can be adapted to increase HCV treatment access. More